Episode
Donanemab Shows Promise for Alzheimer's | Perth News
- Published
- Jul 17, 2026
- Duration seconds
- 106
- Processing state
not_requested- Canonical source
- https://sources.thednn.ai/faa36404c0f32c36
Actions
POST https://stenobird.com/v1/public/podcasts/perth-news-today-2-min-news-the-daily-news-now-7574199/episodes/donanemab-shows-promise-for-alzheimer-s-perth-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/perth-news-today-2-min-news-the-daily-news-now-7574199/donanemab-shows-promise-for-alzheimer-s-perth-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A breakthrough Alzheimer’s drug called donanemab is showing real promise, slowing cognitive decline for up to three years in early-stage patients—some even after treatment ends. In a major study of 1,200 people, those receiving the IV drug saw significantly slower mental decline, with amyloid plaques slashed by 90% and tau markers reduced. But caution is needed: rare but serious side effects like brain swelling and bleeding have occurred, including deaths. Though licensed, it’s not yet on the NHS due to cost concerns, and widespread rollout faces systemic hurdles as dementia cases surge. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/faa36404c0f32c36